![Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile](/docs/US/2022-09-15/US20220288078A1/abs.jpg.600x600.jpg)
- 专利标题： Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
-
申请号： US17536925申请日： 2021-11-29
-
公开(公告)号： US20220288078A1公开(公告)日： 2022-09-15
- 发明人: Hui-Yin Li , James D. Rodgers
- 申请人： Incyte Holdings Corporation , Incyte Corporation
- 申请人地址： US DE Wilmington; US DE Wilmington
- 专利权人： Incyte Holdings Corporation,Incyte Corporation
- 当前专利权人： Incyte Holdings Corporation,Incyte Corporation
- 当前专利权人地址： US DE Wilmington; US DE Wilmington
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; A61P17/12 ; A61P17/06 ; A61P17/08 ; C07D487/04 ; A61K9/00 ; A61K9/20
![Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile](/abs-image/US/2022/09/15/US20220288078A1/abs.jpg.150x150.jpg)
摘要：
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
信息查询
IPC分类:
